Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Pieris Pharmaceuticals
Pieris Pharmaceuticals
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Media
Merck is set to lead pharmaceutical licensing deals in 2018
GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Media
Pieris Pharmaceuticals appoints new Chairman for Board of Directors
Pharmaceutical
Pieris Pharmaceuticals appoints James Geraghty to its Board of Directors
Regulatory
Commercialised anticalin inhaled treatments
Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients
Pieris announces first cancer immunotherapy collaboration
Agreement with Roche leverages proprietary Anticalin technology platform
Pharmaceutical
Pieris Pharmaceuticals appoints Chief Development Officer
Louis Matis takes up the position at the biotechnology company
Research & Development
Pieris Pharmaceuticals and the University of Melbourne receive grant
To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Subscribe now